Cytosorbents Corporation (CTSO) has a negative trailing P/E of -4.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 39.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -21.40%, forward earnings yield 2.55%. PEG 0.08 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -11.6 | -0.27 | -292.38 | 16.89 | - |
| 2017 | -21.2 | 0.62 | 17.49 | 13.41 | 0.19% |
| 2018 | -14.4 | -0.18 | 14.66 | 12.26 | - |
| 2019 | -6.4 | -0.90 | 36.33 | 5.45 | - |
| 2020 | -39.5 | 0.59 | 3.91 | 7.84 | - |
| 2021 | -7.4 | -0.04 | 2.90 | 4.53 | - |
| 2022 | -2.1 | -0.07 | 1.91 | 1.95 | - |
| 2023 | -1.7 | 0.13 | 2.13 | 1.59 | - |
| 2024 | -2.4 | 0.06 | 4.46 | 1.39 | - |
| 2025 | -4.9 | 0.07 | 6.74 | 1.07 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.47 | $8.21M | $-11.94M | -145.5% |
| 2017 | $-0.31 | $13.38M | $-8.46M | -63.2% |
| 2018 | $-0.56 | $20.25M | $-17.21M | -85% |
| 2019 | $-0.60 | $22.77M | $-19.27M | -84.6% |
| 2020 | $-0.20 | $39.45M | $-7.84M | -19.9% |
| 2021 | $-0.57 | $40.11M | $-24.56M | -61.2% |
| 2022 | $-0.75 | $29.36M | $-32.81M | -111.8% |
| 2023 | $-0.65 | $36.35M | $-28.51M | -78.4% |
| 2024 | $-0.38 | $35.59M | $-20.72M | -58.2% |
| 2025 | $-0.13 | $37.06M | $-8.2M | -22.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.17 | $-0.23 – $-0.10 | $40.59M | $40.4M – $40.78M | 2 |
| 2027 | $-0.06 | $-0.06 – $-0.06 | $49.08M | $48.43M – $49.73M | 1 |
| 2028 | $0.02 | $-0.04 – $0.07 | $56.93M | $56.17M – $57.68M | 2 |
| 2029 | $0.14 | $0.14 – $0.14 | $72.71M | $71.75M – $73.67M | 1 |
| 2030 | $0.58 | $0.57 – $0.59 | $133.04M | $131.28M – $134.79M | 1 |
